Skip to main navigation
Skip to search
Skip to main content
Ariel University Home
Help & FAQ
English
עברית
العربية
Home
Profiles
Research units
Research output
Prizes
Activities
Search by expertise, name or affiliation
Ezetimibe added to statin therapy after acute coronary syndromes
IMPROVE-IT Investigators
Department of Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
3606
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Ezetimibe added to statin therapy after acute coronary syndromes'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Simvastatin
100%
Statin Therapy
100%
Acute Coronary Syndrome
100%
Ezetimibe
100%
Low-density Lipoprotein Cholesterol Level
57%
Monotherapy
42%
Lipid-lowering Therapy
28%
Adverse Effects
14%
Placebo
14%
Confidence Interval
14%
Low-density Lipoprotein Cholesterol (LDL-C)
14%
Kaplan-Meier
14%
Event Rate
14%
Cardiovascular Risk
14%
Median Time
14%
Hazard Ratio
14%
Stable Angina
14%
Cardiovascular Events
14%
Rehospitalization
14%
Cardiovascular Outcomes
14%
Nonfatal Myocardial Infarction
14%
Nonfatal Stroke
14%
Absolute Risk Difference
14%
Cardiovascular Mortality
14%
Gallbladder
14%
Non-statins
14%
Coronary Revascularization
14%
Double-blind Randomized Trial
14%
Time-weighted Average
14%
Intestinal Cholesterol Absorption
14%
Pharmacology, Toxicology and Pharmaceutical Science
Simvastatin
100%
Statin (Protein)
100%
Acute Coronary Syndrome
100%
Ezetimibe
100%
Low Density Lipoprotein Cholesterol
71%
Monotherapy
42%
Malignant Neoplasm
14%
Placebo
14%
Heart Infarction
14%
Cerebrovascular Accident
14%
Unstable Angina Pectoris
14%
Hexachlorophene
14%